Last reviewed · How we verify
Piperacillin i.v.
Piperacillin i.v. is a Small molecule drug developed by Allecra. It is currently in Phase 1 development. Also known as: Beta-lactam antibiotic.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Piperacillin i.v. |
|---|---|
| Also known as | Beta-lactam antibiotic |
| Sponsor | Allecra |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients (PHASE1, PHASE2)
- PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN (PHASE2)
- Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam (PHASE2)
- Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion (PHASE4)
- Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers (PHASE1)
- Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia (PHASE4)
- Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Piperacillin i.v. CI brief — competitive landscape report
- Piperacillin i.v. updates RSS · CI watch RSS
- Allecra portfolio CI
Frequently asked questions about Piperacillin i.v.
What is Piperacillin i.v.?
Who makes Piperacillin i.v.?
Is Piperacillin i.v. also known as anything else?
What development phase is Piperacillin i.v. in?
Related
- Manufacturer: Allecra — full pipeline
- Also known as: Beta-lactam antibiotic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing